Evercore ISI initiated coverage of Insulet (PODD) with an Outperform rating and $370 price target Despite new entrants, Insulet’s unique tubeless form factor is “revolutionizing the insulin pump market,” driving significant growth and the company is poised to maintain its leadership due to its strong market position and broad pharmacy access, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- NVDA, LLY, AMD, PODD, DIS: Top 5 Strong Buy “Growth Stocks” for 2026
- 3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 12/8/2025
- Insulet gets FDA clearance for updates to Omnipod 5 Automated Insulin Delivery
- Insulet price target raised to $432 from $428 at Canaccord
- Early notable gainers among liquid option names on November 21st